Cargando…

Based on different immune responses under the glucose metabolizing type of papillary thyroid cancer and the response to anti-PD-1 therapy

Glucose metabolism-related genes play an important role in the development and immunotherapy of many tumours, but their role in thyroid cancer is ambiguous. To investigate the role of glucose metabolism-related genes in the development of papillary thyroid cancer (PTC) and their correlation with the...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Wenjun, Zeng, Yu, Hu, Linfei, Hao, Jiaru, Chen, Yuzheng, Yun, Xinwei, Lin, Qiang, Li, Huashui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9536150/
https://www.ncbi.nlm.nih.gov/pubmed/36211409
http://dx.doi.org/10.3389/fimmu.2022.991656
_version_ 1784802926859911168
author Xie, Wenjun
Zeng, Yu
Hu, Linfei
Hao, Jiaru
Chen, Yuzheng
Yun, Xinwei
Lin, Qiang
Li, Huashui
author_facet Xie, Wenjun
Zeng, Yu
Hu, Linfei
Hao, Jiaru
Chen, Yuzheng
Yun, Xinwei
Lin, Qiang
Li, Huashui
author_sort Xie, Wenjun
collection PubMed
description Glucose metabolism-related genes play an important role in the development and immunotherapy of many tumours, but their role in thyroid cancer is ambiguous. To investigate the role of glucose metabolism-related genes in the development of papillary thyroid cancer (PTC) and their correlation with the clinical outcome of PTC, we collected transcriptomic data from 501 PTC patients in the Cancer Genome Atlas (TCGA). We performed nonnegative matrix decomposition clustering of 2752 glucose metabolism-related genes from transcriptome data and classified PTC patients into three subgroups (C1 for high activation of glucose metabolism, C2 for low activation of glucose metabolism and C3 for moderate activation of glucose metabolism) based on the activation of different glucose metabolism-related genes in 10 glucose metabolism-related pathways. We found a positive correlation between the activation level of glucose metabolism and the tumour mutation burden (TMB), neoantigen number, mRNA stemness index (mRNAsi), age, and tumour stage in PTC patients. Next, we constructed a prognostic prediction model for PTC using six glucose metabolism-related genes (PGBD5, TPO, IGFBPL1, TMEM171, SOD3, TDRD9) and constructed a nomogram based on the risk score and clinical parameters of PTC patients. Both the prognostic risk prediction model and nomogram had high stability and accuracy for predicting the progression-free interval (PFI) in PTC patients. Patients were then divided into high-risk and low-risk groups by risk score. The high-risk group was sensitive to paclitaxel and anti-PD-1 treatment, and the low-risk group was sensitive to sorafenib treatment. We found that the high-risk group was enriched in inflammatory response pathways and associated with high level of immune cell infiltration. To verify the accuracy of the prognostic prediction model, we knocked down PGBD5 in PTC cells and found that the proliferation ability of PTC cells was significantly reduced. This suggests that PGBD5 may be a relatively important oncogene in PTC. Our study constructed a prognostic prediction model and classification of PTC by glucose metabolism-related genes, which provides a new perspective on the role of glucose metabolism in the development and immune microenvironment of PTC and in guiding chemotherapy, targeted therapy and immune checkpoint blockade therapy of PTC.
format Online
Article
Text
id pubmed-9536150
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-95361502022-10-07 Based on different immune responses under the glucose metabolizing type of papillary thyroid cancer and the response to anti-PD-1 therapy Xie, Wenjun Zeng, Yu Hu, Linfei Hao, Jiaru Chen, Yuzheng Yun, Xinwei Lin, Qiang Li, Huashui Front Immunol Immunology Glucose metabolism-related genes play an important role in the development and immunotherapy of many tumours, but their role in thyroid cancer is ambiguous. To investigate the role of glucose metabolism-related genes in the development of papillary thyroid cancer (PTC) and their correlation with the clinical outcome of PTC, we collected transcriptomic data from 501 PTC patients in the Cancer Genome Atlas (TCGA). We performed nonnegative matrix decomposition clustering of 2752 glucose metabolism-related genes from transcriptome data and classified PTC patients into three subgroups (C1 for high activation of glucose metabolism, C2 for low activation of glucose metabolism and C3 for moderate activation of glucose metabolism) based on the activation of different glucose metabolism-related genes in 10 glucose metabolism-related pathways. We found a positive correlation between the activation level of glucose metabolism and the tumour mutation burden (TMB), neoantigen number, mRNA stemness index (mRNAsi), age, and tumour stage in PTC patients. Next, we constructed a prognostic prediction model for PTC using six glucose metabolism-related genes (PGBD5, TPO, IGFBPL1, TMEM171, SOD3, TDRD9) and constructed a nomogram based on the risk score and clinical parameters of PTC patients. Both the prognostic risk prediction model and nomogram had high stability and accuracy for predicting the progression-free interval (PFI) in PTC patients. Patients were then divided into high-risk and low-risk groups by risk score. The high-risk group was sensitive to paclitaxel and anti-PD-1 treatment, and the low-risk group was sensitive to sorafenib treatment. We found that the high-risk group was enriched in inflammatory response pathways and associated with high level of immune cell infiltration. To verify the accuracy of the prognostic prediction model, we knocked down PGBD5 in PTC cells and found that the proliferation ability of PTC cells was significantly reduced. This suggests that PGBD5 may be a relatively important oncogene in PTC. Our study constructed a prognostic prediction model and classification of PTC by glucose metabolism-related genes, which provides a new perspective on the role of glucose metabolism in the development and immune microenvironment of PTC and in guiding chemotherapy, targeted therapy and immune checkpoint blockade therapy of PTC. Frontiers Media S.A. 2022-09-08 /pmc/articles/PMC9536150/ /pubmed/36211409 http://dx.doi.org/10.3389/fimmu.2022.991656 Text en Copyright © 2022 Xie, Zeng, Hu, Hao, Chen, Yun, Lin and Li https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Xie, Wenjun
Zeng, Yu
Hu, Linfei
Hao, Jiaru
Chen, Yuzheng
Yun, Xinwei
Lin, Qiang
Li, Huashui
Based on different immune responses under the glucose metabolizing type of papillary thyroid cancer and the response to anti-PD-1 therapy
title Based on different immune responses under the glucose metabolizing type of papillary thyroid cancer and the response to anti-PD-1 therapy
title_full Based on different immune responses under the glucose metabolizing type of papillary thyroid cancer and the response to anti-PD-1 therapy
title_fullStr Based on different immune responses under the glucose metabolizing type of papillary thyroid cancer and the response to anti-PD-1 therapy
title_full_unstemmed Based on different immune responses under the glucose metabolizing type of papillary thyroid cancer and the response to anti-PD-1 therapy
title_short Based on different immune responses under the glucose metabolizing type of papillary thyroid cancer and the response to anti-PD-1 therapy
title_sort based on different immune responses under the glucose metabolizing type of papillary thyroid cancer and the response to anti-pd-1 therapy
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9536150/
https://www.ncbi.nlm.nih.gov/pubmed/36211409
http://dx.doi.org/10.3389/fimmu.2022.991656
work_keys_str_mv AT xiewenjun basedondifferentimmuneresponsesundertheglucosemetabolizingtypeofpapillarythyroidcancerandtheresponsetoantipd1therapy
AT zengyu basedondifferentimmuneresponsesundertheglucosemetabolizingtypeofpapillarythyroidcancerandtheresponsetoantipd1therapy
AT hulinfei basedondifferentimmuneresponsesundertheglucosemetabolizingtypeofpapillarythyroidcancerandtheresponsetoantipd1therapy
AT haojiaru basedondifferentimmuneresponsesundertheglucosemetabolizingtypeofpapillarythyroidcancerandtheresponsetoantipd1therapy
AT chenyuzheng basedondifferentimmuneresponsesundertheglucosemetabolizingtypeofpapillarythyroidcancerandtheresponsetoantipd1therapy
AT yunxinwei basedondifferentimmuneresponsesundertheglucosemetabolizingtypeofpapillarythyroidcancerandtheresponsetoantipd1therapy
AT linqiang basedondifferentimmuneresponsesundertheglucosemetabolizingtypeofpapillarythyroidcancerandtheresponsetoantipd1therapy
AT lihuashui basedondifferentimmuneresponsesundertheglucosemetabolizingtypeofpapillarythyroidcancerandtheresponsetoantipd1therapy